BioNTech SE ADRUS09075V1026BNTXBNTX
Financials
Market Cap
$22.10B5Y beta
0.22EPS (TTM)
$4.153Free Float
214.95MP/E ratio (TTM)
22.39Revenue (TTM)
$4.13BEBITDA (TTM)
$1.14BFree Cashflow (TTM)
$5.05BPricing
Analyst Ratings
The price target is $121.41 and the stock is covered by 18 analysts.
Buy
9
Hold
8
Sell
1
Information
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.